Bayli DiVita Dean

Bayli DiVita Dean

Auto-generated profile, based on publicly available information

Bayli DiVita Dean

Lillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
CFCatherine Flores
Catherine Flores
TWTyler J. Wildes
Tyler J. Wildes
BDB. DiVita Dean
B. DiVita Dean
GMG. Moore
G. Moore
JDJ. Drake
J. Drake
DMD. Mitchell
D. Mitchell
Extensive clonal T cell expansion is associated with response to immunotherapy.

7 February 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
BDBayli DiVita Dean
Bayli DiVita Dean
TWTyler Wildes
Tyler Wildes
JDJoseph Dean
Joseph Dean
OYOleg Yegorov
Oleg Yegorov
CYChanglin Yang
Changlin Yang
CFCatherine Flores
Catherine Flores
Background: Glioma-induced immune dysregulation of the hematopoietic system has been described in a limited number of studies. In this study, our group further demonstrates that gliomas interrupt the cellular differentiation programming and outcomes of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. HSPCs from glioma-bearing mice are reprogrammed and driven towards expansion of myeloid lineage precursors and myeloid-derived suppressor cells (MDSCs) in secondary lymphoid organs. However, we found this expansion is reversed by immunotherapy. Adoptive cellular therapy (ACT) has been demonstrably efficacious in multiple preclinical models of central nervous system (CNS) malignancies, and here we describe how glioma-induced dysfunction is reversed by this immunotherapeutic platform. Methods: The impact of orthotopic KR158B-luc glioma on HSPCs was evaluated in an unbiased fashion using single cell RNAseq (scRNAseq) of lineage− cells and phenotypically using flow cytometry. Mature myeloid cell frequencies and function were also evaluated using flow cytometry. Finally, ACT containing total body irradiation, tumor RNA-pulsed dendritic cells, tumor-reactive T cells and HSPCs isolated from glioma-bearing or non-tumor-bearing mice were used to evaluate cell fate differentiation and survival. Results: Using scRNAseq, we observed an altered HSPC landscape in glioma-bearing versus non-tumor-bearing mice . In addition, an expansion of myeloid lineage subsets, including granulocyte macrophage precursors (GMPs) and MDSCs, were observed in glioma-bearing mice relative to non-tumor-bearing controls. Furthermore, MDSCs from glioma-bearing mice demonstrated increased suppressive capacity toward tumor-specific T cells as compared with MDSCs from non-tumor-bearing hosts. Interestingly, treatment with ACT overcame these suppressive properties. When HSPCs from glioma-bearing mice were transferred in the context of ACT, we observed significant survival benefit and long-term cures in orthotopic glioma models compared with mice treated with ACT using non-glioma-bearing HSPCs.